12 blood pressure drugs back-ordered, partly because of carcinogen

Three drugmakers each have four blood pressure drugs in short supply after some were recalled in 2022 because of the presence of nitrosamine, which the FDA has labeled as a "probable human carcinogen."

Lupin Pharmaceuticals discontinued some quinapril tablets and recalled others in late December 2022, according to the American Society of Health-System Pharmacists. Pfizer and Solco Healthcare U.S. have their quinapril products on back order and allocation, respectively, and neither could estimate a resupply date. 

Pfizer also reported a recall last April for 11 lots of its quinapril oral tablets, marketed as Accupril, but the drugmaker's current shortage is because of a manufacturing delay, according to the ASHP.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars